Article Text

other Versions

PDF
Carbohydrate Antigen 125: An Emerging Prognostic Risk Factor in Acute Heart Failure?
  1. Julio Nuñez (yulnunez{at}gmail.com)
  1. Hospital Clinico Universitario de Valencia, Spain
    1. Eduardo Núñez
    1. Hospital Clinico Universitario de Valencia, Spain
      1. Luciano Consuegra
      1. Hospital Clinico Universitario de Valencia, Spain
        1. Juan Sanchis
        1. Hospital Clinico Universitario de Valencia, Spain
          1. Vicent Bodí
          1. Hospital Clinico Universitario de Valencia, Spain
            1. Angel Martínez-Brotons
            1. Hospital Clinico Universitario de Valencia, Spain
              1. Vicente Bertomeu-González
              1. Hospital Clinico Universitario de Valencia, Spain
                1. Rocio Robles
                1. Hospital Clinico Universitario de Valencia, Spain
                  1. Maria J Bosch
                  1. Hospital Clinico Universitario de Valencia, Spain
                    1. Lorenzo Fácila
                    1. Hospital Clinico Universitario de Valencia, Spain
                      1. Helene Darmofal
                      1. Hospital Clinico Universitario de Valencia, Spain
                        1. Angel Llácer
                        1. Hospital Clinico Universitario de Valencia, Spain

                          Abstract

                          Objective This study was designed to assess whether Carbohydrate antigen 125 (CA125) circulating levels predict subsequent 6-month all-cause mortality in patients after the index hospitalization for acute heart failure (HF).

                          Design Prospective cohort study.

                          Setting Single teaching center in Spain.

                          Methods We analyzed 529 consecutive patients with acute HF admitted in a single university center. In addition to traditional clinical information, CA125 (U/mL) was measured during the early course of hospitalization. The independent association between baseline CA125 and mortality was assessed with Cox regression analysis. The follow-up was limited to 6-month.

                          Results 349 (66%) patients showed CA125 serum levels higher than 35 U/ml (established cut point value). At 6-month follow-up 89 deaths (16.8%) were identified. A positive trend between mortality and CA125 quartiles was observed; 3.8, 15.2, 22 and 26.5 percent of deaths occurred from quartile 1 to 4 of CA125 (p<0.001). Likewise, there was a monotonic, ascending trend in the risk ratios estimated from the multivariable Cox Model. Compared with the first quartile of CA125, the HR (95% CI) for the second, third and fourth quartiles were 3.25 (1.20-8.79), 4.91 (1.88-12.85) and 8.41 (3.24-21.79) respectively.

                          Conclusions Serum level of CA125 obtained in patients admitted with a diagnosis of acute HF shows to be an independent predictor of mortality up to 6-month follow-up.

                          • Antigen Carbohydrate 125
                          • Heart Failure
                          • Mortality
                          • Risk Stratification
                          • Tumour Marker

                          Statistics from Altmetric.com

                          Request permissions

                          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.